florquinitau F-18, VIZAMYL 400 MBq/mL solution for injection, [18F]PI-2620
IIBSP-HEA-2022-145
Phase 2 small_molecule active
Quick answer
florquinitau F-18, VIZAMYL 400 MBq/mL solution for injection, [18F]PI-2620 for cognitive impairment is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- cognitive impairment
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active